{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:08:18Z","timestamp":1774566498489,"version":"3.50.1"},"reference-count":235,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,12,1]]},"DOI":"10.1086\/380488","type":"journal-article","created":{"date-parts":[[2003,11,17]],"date-time":"2003-11-17T14:59:51Z","timestamp":1069081191000},"page":"1405-1433","source":"Crossref","is-referenced-by-count":785,"title":["Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults"],"prefix":"10.1093","volume":"37","author":[{"given":"Lionel A.","family":"Mandell","sequence":"first","affiliation":[{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott F.","family":"Dowell","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Thomas M.","family":"File","sequence":"additional","affiliation":[{"name":"Summa Health System, Akron, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Musher","sequence":"additional","affiliation":[{"name":"VA Medical Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Whitney","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2003,12,1]]},"reference":[{"key":"2020110410211810600_ref1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1086\/513953","article-title":"Community-acquired pneumonia in adults: guidelines for management. Infectious Diseases Society of America","volume":"26","author":"Bartlett","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/0003-4819-138-2-200301210-00012","article-title":"Testing strategies in the initial management of patients with community-acquired pneumonia","volume":"138","author":"Metlay","year":"2003","journal-title":"Ann Intern Med"},{"key":"2020110410211810600_ref4","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMcp020499","article-title":"Management of community-acquired pneumonia","volume":"347","author":"Halm","year":"2002","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/313959","article-title":"Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group","volume":"31","author":"Mandell","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1067\/mem.2001.115880","article-title":"Clinical policy for the management and risk stratifications of community acquired pneumonia in adults in the emergency department","volume":"38","author":"American College of Emergency Physicians","year":"2001","journal-title":"Ann Emerg Med"},{"issue":"(Suppl 1)","key":"2020110410211810600_ref7","first-page":"192","article-title":"Translating the pneumonia severity index into practice: a trial to influence the admission decision","volume":"17","author":"Fine","year":"2002","journal-title":"J Gen Intern Med"},{"key":"2020110410211810600_ref8","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/archinte.162.11.1278","article-title":"Instability on hospital discharge and the risk of adverse outcome in patients with pneumonia","volume":"162","author":"Halm","year":"2002","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/322632","article-title":"Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada)","volume":"33","author":"Dowell","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1378\/chest.119.1.243","article-title":"Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples","volume":"119","author":"Dom\u00ednguez","year":"2001","journal-title":"Chest"},{"key":"2020110410211810600_ref11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s100960100614","article-title":"Evaluation of a rapid immunochromatographic assay for detection of Streptococcus pneumoniae antigen in urine samples","volume":"20","author":"Burel","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410211810600_ref12","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1128\/JCM.39.10.3495-3498.2001","article-title":"Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia","volume":"39","author":"Murdoch","year":"2001","journal-title":"J Clin Microbiol"},{"key":"2020110410211810600_ref13","first-page":"259","article-title":"Urinary detection of Streptococcus pneumoniae antigen for diagnosis of pneumonia","volume":"25","author":"Farina","year":"2002","journal-title":"New Microbiol"},{"key":"2020110410211810600_ref14","article-title":"Evaluation of the Binax urinary, Gram stain and sputum culture for Streptococcus pneumoniae in patients with community-acquired pneumonia [abstract 262]","volume-title":"Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans)","author":"Yu","year":"2000"},{"key":"2020110410211810600_ref15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/345852","article-title":"Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain","volume":"36","author":"Gutierrez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/00006454-200208000-00020","article-title":"Urinary excretion of pneumococcal cell wall polysaccharide in children","volume":"21","author":"Fadan","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"2020110410211810600_ref17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/00006454-200107000-00018","article-title":"Evaluation of Binax NOW Streptococcus pneumoniae urinary antigen test in children in a community with a high carriage rate of pneumococcus","volume":"20","author":"Adegbola","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"2020110410211810600_ref18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1086\/319205","article-title":"Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients","volume":"32","author":"Dowell","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1378\/chest.119.1.9","article-title":"The urinary antigen test for the diagnosis of pneumococcal pneumonia","volume":"119","author":"Pesola","year":"2001","journal-title":"Chest"},{"key":"2020110410211810600_ref20","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1001\/archinte.161.21.2538","article-title":"A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta lactam antibiotics","volume":"161","author":"Musher","year":"2001","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/00006454-199510000-00013","article-title":"Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease","volume":"14","author":"Friedland","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"2020110410211810600_ref22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJM199508243330802","article-title":"Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain","volume":"333","author":"Pallares","year":"1995","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1086\/516340","article-title":"Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children","volume":"26","author":"Choi","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1086\/520209","article-title":"Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HIV seroprevalence","volume":"29","author":"Turret","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2105\/AJPH.90.2.223","article-title":"Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995\u20131997","volume":"90","author":"Feikin","year":"2000","journal-title":"Am J Public Health"},{"key":"2020110410211810600_ref26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","article-title":"Management of community acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group","volume":"160","author":"Heffelfinger","year":"2000","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref27","volume-title":"Cumulative number of reported probable cases of severe acute respiratory syndrome (SARS)","author":"World Health Organization (WHO)","year":"2003"},{"key":"2020110410211810600_ref28","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.289.14.1775","article-title":"Outbreak of severe acute respiratory syndrome\u2014worldwide, 2003","volume":"289","year":"2003","journal-title":"JAMA"},{"key":"2020110410211810600_ref29","first-page":"241","article-title":"Update: outbreak of severe acute respiratory syndrome\u2014worldwide, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref30","first-page":"226","article-title":"Outbreak of severe acute respiratory syndrome\u2014worldwide, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref31","first-page":"433","article-title":"Cluster of severe acute respiratory syndrome cases among protected health-care workers\u2014Toronto, Canada, April 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref32","volume-title":"Interim domestic guidance on the use of respirators to prevent transmission of SARS. 6 May","author":"Centers for Disease Control and Prevention","year":"2003"},{"key":"2020110410211810600_ref33","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref34","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/423240a","article-title":"Aetiology: Koch's postulates fulfilled for SARS virus","volume":"423","author":"Fouchier","year":"2003","journal-title":"Nature"},{"key":"2020110410211810600_ref36","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1085952","article-title":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome","volume":"300","author":"Rota","year":"2003","journal-title":"Science"},{"key":"2020110410211810600_ref37","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"Updated interim US case definition of severe acute respiratory syndrome (SARS). 18 July"},{"key":"2020110410211810600_ref38","first-page":"391","article-title":"Updated interim surveillance case definition for severe acute respiratory syndrome (SARS) April 29, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref39","author":"World Health Organization","year":"2003","journal-title":"Case definitions for surveillance of severe acute respiratory syndrome (SARS). 1 May"},{"key":"2020110410211810600_ref40","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"key":"2020110410211810600_ref41","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMoa030666","article-title":"A cluster of cases of severe acute respiratory syndrome in Hong Kong","volume":"348","author":"Tsang","year":"2003","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref42","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa030634","article-title":"Identification of severe acute respiratory syndrome in Canada","volume":"348","author":"Poutanen","year":"2003","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1148\/radiol.2282030593","article-title":"Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients","volume":"228","author":"Wong","year":"2003","journal-title":"Radiology"},{"key":"2020110410211810600_ref44","volume-title":"Severe acute respiratory syndrome (SARS) diagnosis\/evaluation. 18 July","author":"Centers for Disease Control and Prevention","year":"2003"},{"key":"2020110410211810600_ref45","first-page":"297","article-title":"Severe acute respiratory syndrome (SARS) and coronavirus testing\u2014United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref46","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1001\/archinte.159.21.2576","article-title":"Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia","volume":"159","author":"Stahl","year":"1999","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref47","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.159.21.2562","article-title":"Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia","volume":"159","author":"Gleason","year":"1999","journal-title":"Arch Intern Med"},{"issue":"(Suppl)","key":"2020110410211810600_ref48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0002-9343(99)00098-4","article-title":"Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978\u20131997","volume":"107","author":"Mufson","year":"1999","journal-title":"Am J Med"},{"key":"2020110410211810600_ref49","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/archinte.161.15.1837","article-title":"Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia","volume":"161","author":"Waterer","year":"2001","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/367541","article-title":"Addition of a macrolide to a \u03b2-lactam based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia","volume":"36","author":"Martinez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0014-2999(01)01321-8","article-title":"Anti-inflammatory effects of macrolide antibiotics","volume":"429","author":"Culic","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"2020110410211810600_ref52","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/367545","article-title":"What is optimal antimicrobial therapy for bacterial pneumococcal pneumonia","volume":"36","author":"File","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref53","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archinte.1997.00440360129015","article-title":"Incidence of community acquired pneumonia requiring hospitalizations: results of a population-based active surveillance study in Ohio. Community-Based Pneumonia Incidence Study Group","volume":"157","author":"Marston","year":"1997","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00005792-199009000-00004","article-title":"New and emerging etiologies for community acquired pneumonia with implications for therapy: a prospective Multicenter study of 359 cases","volume":"69","author":"Fang","year":"1990","journal-title":"Medicine (Baltimore)"},{"key":"2020110410211810600_ref55","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1164\/ajrccm.152.4.7551387","article-title":"Community acquired pneumonia: impact of immune status","volume":"152","author":"Mundy","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110410211810600_ref56","first-page":"297","article-title":"Clinical diagnosis of legionnaires' disease (LD) using a multivariate model [abstract K55]","volume-title":"Program and abstracts of the 35th Interscience on Antimicrobial Agents and Chemotherapy (San Francisco)","author":"Keller","year":"1995"},{"key":"2020110410211810600_ref57","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199709043371006","article-title":"Legionellosis","volume":"337","author":"Stout","year":"1997","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref58","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/archinte.1994.00420210049006","article-title":"Surveillance for legionnaires' disease: risk factors for morbidity and mortality","volume":"154","author":"Marston","year":"1994","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref59","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1086\/338060","article-title":"An outbreak of travel-associated legionnaires disease and Pontiac fever: the need for enhanced surveillance of travel-associated legionellosis in the United States","volume":"185","author":"Benin","year":"2002","journal-title":"J Infect Dis"},{"key":"2020110410211810600_ref60","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1128\/JCM.41.2.838-840.2003","article-title":"Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease","volume":"41","author":"Helbig","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2020110410211810600_ref61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0801.010176","article-title":"A large outbreak of Legionnaires' disease at a flower show, the Netherlands, 1999","volume":"8","author":"Den Boer","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"2020110410211810600_ref62","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s100960050418","article-title":"New directions for future studies of community-acquired pneumonia: optimizing impact on patient care","volume":"18","author":"Vergis","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410211810600_ref63","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1378\/chest.99.2.344","article-title":"Comparative study of Legionella pneumophila and other nosocomial-acquired pneumonias","volume":"99","author":"Roig","year":"1991","journal-title":"Chest"},{"key":"2020110410211810600_ref64","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1378\/chest.113.5.1195","article-title":"Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias","volume":"113","author":"Sopena","year":"1998","journal-title":"Chest"},{"key":"2020110410211810600_ref65","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.120.4.1064","article-title":"Evaluation of the Winthrop-University Hospital criteria to identify Legionella pneumonia","volume":"120","author":"Gupta","year":"2001","journal-title":"Chest"},{"key":"2020110410211810600_ref66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/345529","article-title":"Diagnosis of Legionella infection","volume":"36","author":"Murdoch","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref67","first-page":"1","article-title":"Case definitions for infectious conditions under public health surveillance","volume":"46(RR-10)","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref68","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkg191","article-title":"Legionnaires' disease: a rational approach to therapy","volume":"51","author":"Roig","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref69","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-129-4-199808150-00012","article-title":"Antimicrobial chemotherapy for Legionnaires disease: time for a change","volume":"129","author":"Edelstein","year":"1998","journal-title":"Ann Intern Med"},{"key":"2020110410211810600_ref70","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/BF01695659","article-title":"Delay in appropriate therapy of Legionella pneumonia associated with increased mortality","volume":"15","author":"Heath","year":"1996","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410211810600_ref71","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.283.4.499","article-title":"Impact of respiratory virus infections on persons with chronic underlying conditions","volume":"283","author":"Glezen","year":"2000","journal-title":"JAMA"},{"key":"2020110410211810600_ref72","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"2020110410211810600_ref73","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3201\/eid0809.020084","article-title":"Human metapneumovirus as a cause of community-acquired respiratory illness","volume":"8","author":"Stockton","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"2020110410211810600_ref74","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1086\/367901","article-title":"Human metapneumovirus infections in young and elderly adults","volume":"187","author":"Falsey","year":"2003","journal-title":"J Infect Dis"},{"key":"2020110410211810600_ref75","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0891-5520(20)30408-6","article-title":"Viral pneumonia","volume":"5","author":"Greenberg","year":"1991","journal-title":"Infect Dis Clin North Am"},{"key":"2020110410211810600_ref76","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/thorax.56.4.296","article-title":"Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines","volume":"56","author":"Lim","year":"2001","journal-title":"Thorax"},{"key":"2020110410211810600_ref77","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1386-6532(99)00058-X","article-title":"Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection","volume":"14","author":"Kaiser","year":"1999","journal-title":"J Clin Virol"},{"key":"2020110410211810600_ref78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0166-0934(03)00050-8","article-title":"Evaluation of a rapid test (QuickVue) compared with the shell vial assay for detection of influenza virus clearance after antiviral treatment","volume":"109","author":"Bellei","year":"2003","journal-title":"J Virol Methods"},{"key":"2020110410211810600_ref79","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/archinte.160.21.3243","article-title":"Clinical signs and symptoms predicting influenza infection","volume":"160","author":"Monto","year":"2000","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref80","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"Gubareva","year":"2000","journal-title":"Lancet"},{"key":"2020110410211810600_ref81","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1086\/318537","article-title":"Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir","volume":"183","author":"Gubareva","year":"2001","journal-title":"J Infect Dis"},{"key":"2020110410211810600_ref82","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1001\/archinte.160.21.3234","article-title":"Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults","volume":"160","author":"Kaiser","year":"2000","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref83","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"key":"2020110410211810600_ref84","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment","volume":"282","author":"Hayden","year":"1999","journal-title":"JAMA"},{"key":"2020110410211810600_ref85","first-page":"112","article-title":"Hospitalizing influenza in adults","volume":"19","author":"Kaiser","year":"1999","journal-title":"Curr Clin Top Infect Dis"},{"key":"2020110410211810600_ref86","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1378\/chest.119.6.1717","article-title":"Influenza pneumonia: a descriptive study","volume":"119","author":"Oliveira","year":"2001","journal-title":"Chest"},{"key":"2020110410211810600_ref87","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/clinids\/12.5.788","article-title":"Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review","volume":"12","author":"Haake","year":"1990","journal-title":"Rev Infect Dis"},{"key":"2020110410211810600_ref88","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965359900400404","article-title":"Intravenous ribavirin for Hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group","volume":"4","author":"Chapman","year":"1999","journal-title":"Antivir Ther"},{"key":"2020110410211810600_ref89","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/324619","article-title":"Discriminators between Hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive Hantavirus pulmonary syndrome","volume":"34","author":"Chapman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref90","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.283.5406.1279","article-title":"The looming threat of bioterrorism","volume":"283","author":"Henderson","year":"1999","journal-title":"Science"},{"key":"2020110410211810600_ref91","first-page":"15","volume-title":"Medical management of biological casualties handbook","author":"Eitzen","year":"1998","edition":"3rd ed."},{"key":"2020110410211810600_ref92","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/341902","article-title":"Management of anthrax","volume":"35","author":"Bartlett","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref93","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"2020110410211810600_ref94","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1086\/346035","article-title":"Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses","volume":"36","author":"Kuehnert","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref95","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"key":"2020110410211810600_ref96","first-page":"181","article-title":"Tularemia\u2014United States, 1990\u20132000","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref97","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1001\/jama.285.21.2763","article-title":"Tularemia as a biological weapon: medical and public health management","volume":"285","author":"Dennis","year":"2001","journal-title":"JAMA"},{"key":"2020110410211810600_ref98","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1128\/JCM.40.6.2278-2281.2002","article-title":"Exposure of laboratory workers to Francisella tularensis despite a bioterrorism procedure","volume":"40","author":"Shapiro","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2020110410211810600_ref99","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/clinids\/19.1.42","article-title":"Streptomycin and alternative agents for the treatment of tularemia: review of the literature","volume":"19","author":"Enderlin","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00005792-198507000-00006","article-title":"Tularemia: a 30-year experience with 88 cases","volume":"64","author":"Evans","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"2020110410211810600_ref101","first-page":"39","article-title":"Treatment of tularemia, including pulmonary tularemia, with gentamicin","volume":"121","author":"Mason","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"2020110410211810600_ref102","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1086\/520458","article-title":"Treatment of tularemia with fluoroquinolones: two cases and review","volume":"29","author":"Limaye","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref103","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense","volume":"283","author":"Inglesby","year":"2000","journal-title":"JAMA"},{"key":"2020110410211810600_ref104","first-page":"617","article-title":"Fatal human plague\u2014Arizona and Colorado, 1996","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref105","first-page":"37","article-title":"Sensitivity of Yersinia pestis to antibiotics: 277 strains isolated in Madagascar between 1926 and 1989","volume":"56","author":"Rasoamanana","year":"1989","journal-title":"Arch Inst Pasteur Madagascar"},{"key":"2020110410211810600_ref106","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/AAC.38.3.481","article-title":"Assessment of a fluoroquinolone, three beta lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection","volume":"38","author":"Bonacorsi","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref107","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jac\/41.2.301","article-title":"Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection","volume":"41","author":"Russell","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref108","first-page":"535","article-title":"Pneumonia and influenza death rates, United States, 1979\u20131994","volume":"44","year":"1995","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref109","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0002-9343(98)00262-9","article-title":"Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention","volume":"105","author":"Muder","year":"1998","journal-title":"Am J Med"},{"key":"2020110410211810600_ref110","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1086\/319746","article-title":"Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in Eastern Finland","volume":"32","author":"Joikinen","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref111","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1164\/ajrccm.160.2.9808045","article-title":"Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity","volume":"160","author":"Ruiz","year":"1999","journal-title":"Am J Resp Crit Care Med"},{"key":"2020110410211810600_ref112","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0002-9343(94)90060-4","article-title":"Risk factors for pneumonia in the elderly","volume":"96","author":"Koivula","year":"1994","journal-title":"Am J Med"},{"key":"2020110410211810600_ref113","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/archinte.159.17.2058","article-title":"Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities","volume":"159","author":"Loeb","year":"1999","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref114","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/archinte.1997.00440340089009","article-title":"Influence of age on symptoms at presentation in patients with community-acquired pneumonia","volume":"157","author":"Metlay","year":"1997","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1532-5415.1985.tb01775.x","article-title":"Community-acquired pneumonia requiring hospitalization: is it different in the elderly?","volume":"33","author":"Marrie","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"2020110410211810600_ref116","doi-asserted-by":"crossref","first-page":"518","DOI":"10.7326\/0003-4819-123-7-199510010-00008","article-title":"The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature","volume":"123","author":"Gross","year":"1995","journal-title":"Ann Intern Med"},{"key":"2020110410211810600_ref117","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1056\/NEJMoa025028","article-title":"Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly","volume":"348","author":"Nichol","year":"2003","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/175.1.1","article-title":"Influenza vaccination of healthcare workers in long-term care hospitals reduces the mortality of elderly patients","volume":"175","author":"Potter","year":"1997","journal-title":"J Infect Dis"},{"key":"2020110410211810600_ref119","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(99)05190-9","article-title":"Effects of influenza vaccination of healthcare workers on mortality of elderly people in long term care: a randomized controlled trial","volume":"355","author":"Carman","year":"2000","journal-title":"Lancet"},{"key":"2020110410211810600_ref120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(97)00149-6","article-title":"Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial","volume":"103","author":"Koivula","year":"1997","journal-title":"Am J Med"},{"key":"2020110410211810600_ref121","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJM198611203152104","article-title":"Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study","volume":"315","author":"Simberkoff","year":"1986","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref122","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0140-6736(97)07358-3","article-title":"Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-age and elderly people","volume":"351","author":"\u00f6rtqvist","year":"1998","journal-title":"Lancet"},{"key":"2020110410211810600_ref123","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1086\/318709","article-title":"Nonspecificity of assaying for IgG to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia","volume":"32","author":"Musher","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref124","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archinte.1947.00220110058004","article-title":"Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide; results of a six year study","volume":"79","author":"Kaufman","year":"1947","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref125","first-page":"437","article-title":"Essai clinique du vaccin antipneumococcique chez des personnes \u00e2g\u00e9es vivant en institution","volume":"33","author":"Gaillat","year":"1985","journal-title":"Rev Epid\u00e9miol Sant\u00e9 Publique"},{"key":"2020110410211810600_ref126","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jama.1993.03510150060030","article-title":"Polysaccharide pneumococcal vaccine efficacy: an evaluation of current recommendations","volume":"270","author":"Butler","year":"1993","journal-title":"JAMA"},{"key":"2020110410211810600_ref127","doi-asserted-by":"crossref","first-page":"653","DOI":"10.7326\/0003-4819-108-5-653","article-title":"The clinical effectiveness of pneumococcal vaccine in the elderly","volume":"108","author":"Sims","year":"1988","journal-title":"Ann Intern Med"},{"key":"2020110410211810600_ref128","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJM199111213252101","article-title":"The protective efficacy of polyvalent pneumococcal polysaccharide vaccine","volume":"325","author":"Shapiro","year":"1991","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref129","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1001\/archinte.1995.00430210086013","article-title":"Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study","volume":"155","author":"Farr","year":"1995","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref130","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJMoa022678","article-title":"Effectiveness of pneumococcal polysaccharide vaccine in older adults","volume":"348","author":"Jackson","year":"2003","journal-title":"New Engl J Med"},{"key":"2020110410211810600_ref131","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease following the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref132","first-page":"68","article-title":"Facilitating influenza and pneumococcal vaccination through standing orders programs","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"(RR-8)","key":"2020110410211810600_ref133","first-page":"1","article-title":"Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"52","author":"Bridges","year":"2003","journal-title":"MMWR Recomm Rep"},{"issue":"(RR-13)","key":"2020110410211810600_ref134","first-page":"1","article-title":"Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"52","author":"Harper","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"2020110410211810600_ref135","first-page":"1","article-title":"Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref136","doi-asserted-by":"crossref","first-page":"960","DOI":"10.7326\/0003-4819-138-12-200306170-00007","article-title":"Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race","volume":"138","author":"Sisk","year":"2003","journal-title":"Ann Intern Med"},{"issue":"(Suppl)","key":"2020110410211810600_ref137","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/324527","article-title":"Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia","volume":"34","author":"Lynch","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"(Suppl 1)","key":"2020110410211810600_ref138","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1086\/324525","article-title":"Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999\u20132000","volume":"34","author":"Thornsberry","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref139","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.286.15.1857","article-title":"Macrolide resistance among invasive Streptococcus pneumoniae isolates","volume":"286","author":"Hyde","year":"2001","journal-title":"JAMA"},{"key":"2020110410211810600_ref140","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.45.6.1721-1729.2001","article-title":"Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999\u20132000, including a comparison of resistance rates since 1994\u20131995","volume":"45","author":"Doern","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref141","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/mdr.1998.4.325","article-title":"Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States","volume":"4","author":"Corso","year":"1998","journal-title":"Microb Drug Resist"},{"key":"2020110410211810600_ref142","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1086\/313452","article-title":"Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in The United States in 1994\u20131995","volume":"29","author":"Shortridge","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref143","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1128\/AAC.44.12.3395-3401.2000","article-title":"Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America","volume":"44","author":"Tait-Kamradt","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref144","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM200202213460820","article-title":"Emergence of macrolide resistance during treatment of pneumococcal pneumonia","volume":"346","author":"Musher","year":"2002","journal-title":"New Engl J Med"},{"key":"2020110410211810600_ref145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3201\/eid0904.020268","article-title":"Antimicrobial drug prescription in ambulatory care settings, United States, 1992\u20132000","volume":"9","author":"McCaig","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"2020110410211810600_ref146","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/315853","article-title":"The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population based assessment","volume":"182","author":"Gay","year":"2000","journal-title":"J Infect Dis"},{"key":"2020110410211810600_ref147","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1128\/AAC.45.12.3334-3340.2001","article-title":"Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998\u20131999) multicenter surveillance study in Spain","volume":"45","author":"Perez-Trallero","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"(Suppl 2)","key":"2020110410211810600_ref148","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1086\/320181","article-title":"Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"32","author":"Hoban","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref149","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(67)92150-2","article-title":"Pneumococcus resistant to erythromycin and lincomycin","volume":"1","author":"Dixon","year":"1967","journal-title":"Lancet"},{"key":"2020110410211810600_ref150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/313976","article-title":"Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin","volume":"31","author":"Fogarty","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref151","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/318157","article-title":"Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin","volume":"31","author":"Kelley","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref152","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae","volume":"35","author":"Lonks","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref153","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1021\/jm970852i","article-title":"Conformational analysis of ketolide, conformations of RU 004 in solution and bound to bacterial ribosomes","volume":"27","author":"Bertho","year":"1998","journal-title":"J Med Chem"},{"key":"2020110410211810600_ref154","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2958.1999.01202.x","article-title":"The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA","volume":"31","author":"Hansen","year":"1999","journal-title":"Mol Microbiol"},{"key":"2020110410211810600_ref155","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/AAC.46.9.2727-2734.2002","article-title":"Will resistance to ketolides develop in Streptococcus pneumoniae?","volume":"46","author":"Leclercq","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref156","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1128\/AAC.42.3.624","article-title":"Susceptibilities of penicillin and erythromycin susceptible and resistant pneumococci to MHR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents","volume":"42","author":"Panduch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref157","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/jac\/44.4.445","article-title":"In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci","volume":"44","author":"Wooton","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref158","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1128\/AAC.43.1.90","article-title":"In-vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia","volume":"43","author":"Edelstein","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref159","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jac\/48.3.403","article-title":"In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae","volume":"48","author":"Miyashita","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1469-0691.2001.00213.x","article-title":"Uptake and intracellular activity of Ketolide HMR 3647 in human phagocytic and non phagocytic cells","volume":"7","author":"Pascual","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"2020110410211810600_ref161","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.46.3.917-921.2002","article-title":"Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers","volume":"46","author":"Kadota","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref162","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/rmed.2003.1492","article-title":"Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis","volume":"97","author":"Hagberg","year":"2003","journal-title":"Respir Med"},{"key":"2020110410211810600_ref163","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once daily telithromycin compared with high-dose amoxicillin in the treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"2020110410211810600_ref164","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once daily oral therapy with telithromycin compared with trovafloxacin in the treatment of community-acquired pneumonia","volume":"57","author":"Pullman","year":"2003","journal-title":"Int J Clin Pract"},{"key":"2020110410211810600_ref165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network","volume":"341","author":"Chen","year":"1999","journal-title":"N Engl J Med"},{"issue":"(Suppl 3)","key":"2020110410211810600_ref166","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/1120009X.2002.11782350","article-title":"The rise of fluoroquinolone resistance: fact or fiction?","volume":"14","author":"Ferraro","year":"2002","journal-title":"J Chemother"},{"key":"2020110410211810600_ref167","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/48.5.659","article-title":"Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000","volume":"48","author":"Ho","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref168","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/AAC.46.5.1295-1301.2002","article-title":"Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000","volume":"46","author":"Low","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref169","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/AAC.46.2.371-377.2002","article-title":"Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and eastern European countries","volume":"46","author":"Nagai","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref170","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1128\/AAC.46.8.2671-2675.2002","article-title":"Incidence, epidemiology and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia","volume":"46","author":"Pankuch","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"(Suppl 1)","key":"2020110410211810600_ref171","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1086\/324525","article-title":"Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999\u20132000","volume":"34","author":"Thornsberry","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref172","first-page":"360","article-title":"Emerging resistance in respiratory tract isolates of Streptococcus pneumoniae (SP) in Canada [abstract L992]","volume-title":"Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego)","author":"Tang","year":"2002"},{"key":"2020110410211810600_ref173","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/AAC.46.3.680-688.2002","article-title":"Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994\u20131995","volume":"46","author":"Brueggemann","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref174","first-page":"800","article-title":"Resistance of Streptococcus pneumoniae to fluoroquinolones\u2014United States, 1995\u20131999","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020110410211810600_ref175","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1128\/AAC.45.4.1037-1042.2001","article-title":"Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis","volume":"45","author":"Sahm","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref176","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1128\/AAC.44.9.2521-2524.2000","article-title":"Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States","volume":"44","author":"Sahm","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref177","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1086\/321847","article-title":"Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumniae in the United States","volume":"33","author":"Doern","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref178","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1128\/AAC.47.7.2145-2151.2003","article-title":"Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data","volume":"47","author":"Hsueh","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref179","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/infdis\/163.6.1273","article-title":"Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979\u20131987. The Pneumococcal Surveillance Working Group","volume":"163","author":"Spika","year":"1991","journal-title":"J Infect Dis"},{"key":"2020110410211810600_ref180","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMoa012122","article-title":"Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia","volume":"346","author":"Davidson","year":"2002","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref181","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1046\/j.1532-5415.2003.51501.x","article-title":"Whitney CG, and the Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long term care facilities and in the community","volume":"51","author":"Kupronis","year":"2003","journal-title":"J Amer Ger Society"},{"key":"2020110410211810600_ref182","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1001\/jama.1997.03550230056037","article-title":"Quality of care, process and outcomes in elderly patients with pneumonia","volume":"278","author":"Meehan","year":"1997","journal-title":"JAMA"},{"key":"2020110410211810600_ref183","article-title":"Timing of antibiotic administration and outcomes for Medicare patients hospitalized with pneumonia","volume-title":"Arch Intern Med (in press).","author":"Houck"},{"key":"2020110410211810600_ref184","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.1990.03450150069033","article-title":"Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system","volume":"264","author":"Kahn","year":"1990","journal-title":"JAMA"},{"key":"2020110410211810600_ref185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0097-5990(16)30605-4","article-title":"Pneumonia mortality reduction and quality improvement in a community based hospital","volume":"19","author":"McGarvey","year":"1993","journal-title":"Quality Rev Bull"},{"key":"2020110410211810600_ref186","first-page":"31","article-title":"Timing is everything: impact of emergency department care on hospital length of stay","volume":"7","author":"Rosenstein","year":"2000","journal-title":"J Clinical Outcomes Management"},{"key":"2020110410211810600_ref187","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/archinte.162.6.682","article-title":"Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay with community acquired pneumonia: link between quality of care and resource utilization","volume":"162","author":"Battleman","year":"2002","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref188","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM200003093421002","article-title":"Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team","volume":"342","author":"Nuorti","year":"2000","journal-title":"N Engl J Med"},{"key":"2020110410211810600_ref189","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1128\/AAC.41.6.1399","article-title":"Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers","volume":"41","author":"Rodvold","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref190","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1128\/AAC.46.5.1425-1434.2002","article-title":"Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia","volume":"46","author":"Tessier","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref191","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0149-2918(02)85148-7","article-title":"A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia","volume":"24","author":"Gotfried","year":"2002","journal-title":"Clin Ther"},{"key":"2020110410211810600_ref192","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archinte.160.9.1294","article-title":"Azithromycin vs-cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter study","volume":"160","author":"Vergis","year":"2000","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref193","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0149-2918(02)80034-0","article-title":"A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community acquired pneumonia","volume":"24","author":"Frank","year":"2002","journal-title":"Clin Ther"},{"key":"2020110410211810600_ref194","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/48.5.691","article-title":"Meta-analysis of randomized controlled trials of the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections","volume":"48","author":"Contopoulos-Ioannidis","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref195","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1164\/ajrccm.159.6.9808049","article-title":"Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae","volume":"159","author":"Ewig","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110410211810600_ref196","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkg116","article-title":"Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams","volume":"51","author":"Van Kerkhoven","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref197","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1378\/chest.118.6.1839-a","article-title":"Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy","volume":"118","author":"Waterer","year":"2000","journal-title":"Chest"},{"key":"2020110410211810600_ref198","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1128\/JCM.39.1.367-369.2001","article-title":"Use of penicillin MICs to predict in vitro activity of other \u03b2-lactam antimicrobial agents against Streptococcus pneumoniae","volume":"39","author":"Brueggeman","year":"2001","journal-title":"J Clin Microbiol"},{"key":"2020110410211810600_ref199","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1086\/516366","article-title":"Once-daily sparfloxacin versus high dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults","volume":"26","author":"Aubier","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/00003495-200363020-00005","article-title":"International guidelines for treatment of community-acquired pneumonia in adults: the role of macrolides","volume":"63","author":"File","year":"2003","journal-title":"Drugs"},{"key":"2020110410211810600_ref201","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10096-003-0898-2","article-title":"Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections","volume":"22","author":"Fernandez-Sabe","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410211810600_ref202","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/107662901750152864","article-title":"Usefulness of beta-lactam therapy for community-acquired pneumonia in the era of drug resistant Streptococcus pneumoniae a randomized study of amoxicillin-clavulanate and ceftriaxone","volume":"7","author":"Roson","year":"2001","journal-title":"Microb Drug Resist"},{"key":"2020110410211810600_ref203","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0149-2918(02)80084-4","article-title":"A comparison of cefditoren pivoxil and amoxicillin\/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study","volume":"24","author":"Fogarty","year":"2002","journal-title":"Clin Ther"},{"key":"2020110410211810600_ref204","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0149-2918(02)80083-2","article-title":"Cefditoren pivoxil vs-cefpodoxime proxetil for community-acquired pneumonia: results of a multi-center, prospective, randomized, double blind study","volume":"24","author":"Van Zyl","year":"2002","journal-title":"Clin Ther"},{"key":"2020110410211810600_ref205","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/dkf076","article-title":"Activity of cefditoren against respiratory pathogens","volume":"50","author":"Clark","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref206","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1086\/341983","article-title":"Doxycycline for treatment of community-acquired pneumonia","volume":"35","author":"Johnson","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref207","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archinte.163.7.797","article-title":"Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting","volume":"163","author":"Malcolm","year":"2003","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref208","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0732-8893(02)00391-7","article-title":"Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999\u20132000","volume":"43","author":"White","year":"2002","journal-title":"Diag Microbiol Infect Dis"},{"key":"2020110410211810600_ref209","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid0901.020277","article-title":"Maintaining fluoroquinolone class efficacy: review of influencing factors","volume":"9","author":"Scheld","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"2020110410211810600_ref210","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/AAC.47.1.292-296.2003","article-title":"Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team","volume":"47","author":"Jones","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref211","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0732-8893(02)00447-9","article-title":"Oral gatifloxacin in outpatient community-acquired pneumonia: results from Tea CES, a community-based, open-label multicenter study","volume":"44","author":"Gotfried","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020110410211810600_ref212","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jama.283.6.749","article-title":"A controlled trial of a critical pathway for treating community-acquired pneumonia","volume":"283","author":"Marrie","year":"2000","journal-title":"JAMA"},{"key":"2020110410211810600_ref213","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1128\/AAC.46.6.1746-1754.2002","article-title":"Randomized controlled trial of sequential intravenous and oral moxifloxacin compared to sequential IV and oral co-amoxiclav with or without clarithromycin in patients with community acquired pneumonia requiring initial parenteral treatment","volume":"46","author":"Finch","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref214","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","article-title":"A multicenter, randomized study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or defuroxime axetil in treatment of adults with community-acquired pneumonia","volume":"41","author":"File","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410211810600_ref215","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1345\/aph.1C167","article-title":"Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis","volume":"36","author":"Salkind","year":"2002","journal-title":"Ann Pharmacother"},{"key":"2020110410211810600_ref216","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1086\/322658","article-title":"A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae","volume":"33","author":"Weiss","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref217","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1086\/319222","article-title":"Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae a case control study","volume":"32","author":"Ho","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref218","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/367935","article-title":"The role of clonality in the global spread of fluoroquinolone-resistant bacteria","volume":"36","author":"Klugman","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref219","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3201\/eid0806.010275","article-title":"Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep","volume":"8","author":"Quale","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"2020110410211810600_ref220","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkg106","article-title":"Spain (14-5) international multiresistant Streptococcus pneumoniae clone resistant to fluoroquinolones and other families of antibiotics","volume":"51","author":"Perez-Trallero","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref221","doi-asserted-by":"crossref","first-page":"466","DOI":"10.7326\/0003-4819-98-4-466","article-title":"Clindamycin compared with penicillin for the treatment of anaerobic lung abscess","volume":"98","author":"Levison","year":"1983","journal-title":"Ann Intern Med"},{"key":"2020110410211810600_ref222","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/archinte.1990.00390230077010","article-title":"Clindamycin vs-enicillin for anaerobic lung infections: high rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus","volume":"150","author":"Gudiol","year":"1990","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref223","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archinte.163.4.467","article-title":"Clinical and epidemiologic features of group A streptococcal pneumonia in Ontario Canada","volume":"163","author":"Muller","year":"2003","journal-title":"Arch Intern Med"},{"key":"2020110410211810600_ref224","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nm839","article-title":"Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States","volume":"9","author":"McCormick","year":"2003","journal-title":"Nat Med"},{"key":"2020110410211810600_ref225","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110410211810600_ref226","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1086\/377534","article-title":"An international prospective study of pneumococcal bacteremia correlation with in vitro resistance, antibiotics administered, and clinical outcome","volume":"37","author":"Yu","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref227","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/49.2.399","article-title":"In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antimicrobials including cefotaxime","volume":"49","author":"Fuchs","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref228","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jac\/dkg153","article-title":"Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin","volume":"51","author":"Fogarty","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref229","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0924-8579(01)00359-4","article-title":"Efficacy and safety of gemifloxacin 320 mg once daily for 7 days in the treatment of adult lower respiratory tract infections","volume":"18","author":"Ball","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410211810600_ref230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/48.1.67","article-title":"Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin","volume":"48","author":"File","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2020110410211810600_ref231","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0149-2918(02)80088-1","article-title":"Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone\/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability","volume":"24","author":"Lode","year":"2002","journal-title":"Clin Ther"},{"key":"2020110410211810600_ref232","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0149-2918(02)80078-9","article-title":"A prospective randomized double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia","volume":"24","author":"Vetter","year":"2002","journal-title":"Clin Ther"},{"key":"2020110410211810600_ref233","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/339543","article-title":"A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults","volume":"34","author":"Ortiz-Ruiz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410211810600_ref234","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7326\/0003-4819-138-2-200301210-00015","article-title":"Linezolid: the first oxazolidinones antimicrobial","volume":"138","author":"Moellering","year":"2003","journal-title":"Ann Intern Med"},{"key":"2020110410211810600_ref235","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/0036554021000026933","article-title":"Linezolid vs-ceftriaxone\/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia","volume":"34","author":"San Pedro","year":"2002","journal-title":"Scand J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/37\/11\/1405\/34126131\/37-11-1405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/37\/11\/1405\/34126131\/37-11-1405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T11:59:33Z","timestamp":1704974373000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/37\/11\/1405\/370614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,1]]},"references-count":235,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2003,12,1]]},"published-print":{"date-parts":[[2003,12,1]]}},"URL":"https:\/\/doi.org\/10.1086\/380488","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,12]]},"published":{"date-parts":[[2003,12,1]]}}}